MedTrace Logo

Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer

NCT00109811 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-01-23

No results posted yet for this study

Summary

This phase II trial is studying how well vaccine therapy works in treating patients with recurrent prostate cancer. Vaccines made from peptides may help the body build an effective immune response to kill tumor cells

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer

Interventions

BIOLOGICAL

PSA:154-163(155L) peptide vaccine

Given subcutaneously

BIOLOGICAL

incomplete Freund's adjuvant

Given subcutaneously

OTHER

laboratory biomarker analysis

Correlative studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • H. Richard Alexander · University of Maryland Greenebaum Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00109811 on ClinicalTrials.gov